US Stock MarketDetailed Quotes

ACRS Aclaris Therapeutics

Watchlist
  • 2.330
  • +0.130+5.91%
Close Feb 14 16:00 ET
  • 2.320
  • -0.010-0.43%
Post 20:01 ET
249.35MMarket Cap-4.48P/E (TTM)

About Aclaris Therapeutics Company

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Company Profile

SymbolACRS
Company NameAclaris Therapeutics
Listing DateOct 7, 2015
Issue Price11.00
Founded2012
CEODr. Neal Walker, D.O.
MarketNASDAQ
Employees91
Fiscal Year Ends12-31
Address701 Lee Road,Suite 103
CityWayne
ProvincePennsylvania
CountryUnited States of America
Zip Code19087
Phone1-484-324-7933

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Neal Walker, D.O.
  • Chairman of the Board and Interim Chief Executive Officer
  • 73.50K
  • Dr. Joseph Monahan, PhD
  • Chief Scientific Officer
  • 2.26M
  • Dr. Hugh Davis, PhD
  • President, Chief Operating Officer and Director
  • --
  • Kevin Balthaser
  • Chief Financial Officer and Principal Accounting Officer
  • 2.34M
  • James Loerop
  • Chief Business Officer
  • 2.33M
  • Dr. Anand Mehra, M.D.
  • Independent Director
  • 194.38K
  • Vincent J. Milano
  • Independent Director
  • 180.38K
  • Christopher Molineaux
  • Lead Independent Director
  • 206.88K
  • Dr. Maxine Gowen,PhD
  • Independent Director
  • 206.38K
  • Dr. Andrew N. Schiff, M.D.
  • Independent Director
  • 186.38K
  • William D. Humphries
  • Independent Director
  • 177.38K

Trending Stocks

Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio? Show More